HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

eptifibatide (Integrilin)

Subscribe to New Research on eptifibatide

used in clinical studies as a platelet glycoprotein IIB/IIIA antagonist

Also Known As:

Integrilin; Cor brand of eptifibatide; Essex brand of eptifibatide; GlaxoSmithKline UK brand of eptifibatide; Integrelin; Key brand of eptifibatide; Pfizer brand of eptifibatide; epifibatide; epifibratide

Networked: 439 relevant articles (52 outcomes, 158 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 22950
  - eptifibatide: 439

Experts

1.	Harrington, Robert A: 31 articles (10/2013 - 01/2002)
2.	Califf, Robert M: 22 articles (04/2014 - 01/2002)
3.	Gibson, C Michael: 21 articles (04/2014 - 04/2003)
4.	Califf, R M: 20 articles (07/2002 - 01/2000)
5.	Armstrong, Paul W: 19 articles (04/2014 - 01/2002)
6.	Harrington, R A: 19 articles (07/2002 - 01/2000)
7.	Topol, E J: 19 articles (02/2002 - 01/2000)
8.	Giugliano, Robert P: 18 articles (04/2014 - 04/2003)
9.	Newby, L Kristin: 18 articles (04/2014 - 06/2003)
10.	Lincoff, A M: 14 articles (07/2002 - 02/2000)

Related Diseases

1.	Acute Coronary Syndrome 09/01/2013 - "Consistent with previous literature, upstream treatment with eptifibatide was associated with improved outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients treated with PCI; however, a nonsignificant interaction term precludes a definite conclusion." 01/01/2006 - "Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to standard care is effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI). " 01/01/2005 - "Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to standard care is effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI). " 11/01/2007 - "The alphaIIbbeta3 antagonist eptifibatide is an effective treatment for patients with acute coronary syndromes (ACS). " 09/01/2000 - "PURSUIT was a double-blind, randomized trial that examined the efficacy of eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for < or =96 h) versus placebo among patients who had acute coronary syndromes but not persistent ST-segment elevation. "
2.	Myocardial Infarction 09/01/2000 - "Eptifibatide therapy was associated with a significant reduction in the incidence of the primary endpoint--a composite of death or myocardial infarction at 30 days (14.2 vs. 15.7% in the placebo group; p = 0.042). " 06/01/2007 - "In patients with ST-segment elevation myocardial infarction (STEMI), eptifibatide has been studied as adjunct to primary PCI and improved epicardial flow and tissue reperfusion. " 12/01/2004 - "The PURSUIT trial provided evidence that eptifibatide decreases death or non-fatal myocardial infarction (MI) in the main group and in the diabetic subgroup. " 09/01/2014 - "The appropriate timing of eptifibatide initiation for acute ST segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) remains unclear. " 09/01/2013 - "After multivariable adjustment, compared with delayed provisional use, routine early eptifibatide was associated with lower rate of 30-day death or myocardial infarction (MI) after PCI (hazard ratio [HR] 0.80, 95% CI 0.68-0.95) but not with medical management (HR 0.97, 95% CI 0.74-1.29); PCI × randomized treatment interaction term P = .24. "
3.	Unstable Angina 03/01/1999 - "Eptifibatide is also beneficial in patients undergoing PCI, whether or not they have unstable angina or non-Q-wave MI. " 11/01/1996 - "To test this hypothesis, we investigated retrospectively the results of a trial on Integrelin in unstable angina. " 01/01/2002 - "The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy." 04/15/1999 - "Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy." 07/01/2002 - "These data suggest that eptifibatide benefited unstable angina patients more than myocardial infarction patients, especially among those who underwent early percutaneous coronary intervention, and support its use as concomitant therapy with early percutaneous coronary intervention especially in female myocardial infarction patients."
4.	Hemorrhage 02/01/2015 - "A catheterization laboratory-only eptifibatide regimen is commonly used in clinical practice and is associated with a significant reduction in bleeding complications in patients undergoing contemporary percutaneous coronary intervention." 09/10/2013 - "The amount by which TIMI major bleeding was increased with early vs. delayed provisional eptifibatide use was significantly greater with increasing age (p interaction=0.02), but the age×treatment interactions were not significant for GUSTO moderate/severe bleeding or transfusion (p interaction=0.33 and 0.54, respectively). " 12/01/2009 - "The study aimed to determine the impact on eptifibatide-associated bleeding by implementing a computerized dosing algorithm in the cardiac catheterization suite. " 11/01/2009 - "In the large EARLY-ACS trial upstream therapy with eptifibatide in high risk with NSTE-ACS did not improve ischaemic complications but was associated with an increase in bleeding complications. " 06/20/2006 - "Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial."
5.	Ischemia 06/19/2002 - "Hamsters were treated with saline, or abiciximab or eptifibatide or these drugs combined with t-PA infused intravenously 10 minutes before ischemia and through reperfusion. " 06/20/2006 - "Eptifibatide improved myocardial perfusion and reduced the duration of post-PCI ischemia but was associated with higher minor bleeding and transfusion rates. " 02/18/2004 - "The dose-confirmation regimen of reduced-dose tenecteplase plus high-dose eptifibatide was associated with a faster median time to stable ST-segment recovery (55 vs. 98 min, p = 0.06), improved stable ST-segment recovery by 2 h (89.6% vs. 67.7%, p = 0.02), and less recurrent ischemia (34.0% vs. 57.1%, p = 0.05) when compared with full-dose tenecteplase. " 10/01/2000 - "Five hours after abciximab was discontinued, platelet count returned to normal (191,000/mm3) and eptifibatide was started because of persistent electrocardiographic evidence of ischemia. " 12/28/2000 - "Patients with non-ST-segment elevation MI observed in the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO)-IIB and Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trials also fared better with an ischemia-guided strategy. "

Related Drugs and Biologics

1.	eptifibatide (Integrilin)
2.	Glycoproteins (Glycoprotein)
3.	tirofiban (Aggrastat)
4.	Enoxaparin (Lovenox)
5.	Heparin (Liquaemin)
6.	abciximab (ReoPro)
7.	Platelet Membrane Glycoprotein IIb
8.	Aspirin (Acetylsalicylic Acid)
9.	clopidogrel (Plavix)
10.	tenecteplase

Related Therapies and Procedures

1.	Stents
2.	Drug-Eluting Stents
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Thrombolytic Therapy
5.	Resuscitation